Difference between revisions of "Part:BBa K2812001"

Latest revision as of 01:24, 17 October 2018

Coding sequence for trunctated Lysostaphin

The biobrick contains the coding domain for truncated lysostaphin, based on the coding sequence derived from BBa_K748002. TU-Eindhoven 2018 used this part to produce lysostaphin from Escherichia coli to kill Staphylococcus aureus biofilms for the treatment of wound infections. For more information about our project, please visit our [http://2018.igem.org/Team:TU-Eindhoven wiki].

Usage & Biology

Lysostaphin

Lysostaphin is an antimicrobial agent produced by Staphylococcus simulans. It targets the cell wall peptidoglycan found in certain Staphylococci by cleaving its cross-linking pentaglycine bridges. Among others, it is effective for degrading Staphylocuccus aureus biofilms.¹ The encoding part of the lysostaphin has been derived from BBa_K748002, which was made by iGEM Harbin 2012 and was also used by iGEM Stockholm 2016. iGEM Eindhoven 2018 codon optimized this lysostaphin construct. Lysostaphin belongs to the major class of antimicrobial proteins and peptides known as bacteriocins. Bacteriocins are proteins or peptides produced by bacteria, displaying a bactericidal activity against other subpopulations of bacteria.² The cell wall degradation capability of lysostaphin derives from its endopeptidase activity on pentaglycine cross-bridges in the peptidoglycan layer. Specific cleavage between the third and fourth glycine residue leads to the destruction of the peptidoglycan layer and subsequent lysis of the bacteria.

Sources

1) Tossavainen, H., Raulinaitis, V., Kauppinen, L., Pentikäinen, U., Maaheimo, H., & Permi, P. (2018). Structural and Functional Insights Into Lysostaphin–Substrate Interaction. Front Mol Biosci.

2) Bastos, M. d., Coutinho, B. G., & Coelho, M. L. (2010). Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals (Basel), 1139–1161.

Sequence and Features

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
INCOMPATIBLE WITH RFC[25]
Illegal AgeI site found at 126
1000
COMPATIBLE WITH RFC[1000]

@@ Line 3: / Line 3: @@
 <partinfo>BBa_K2812001 short</partinfo>
-The biobrick contains the coding domain for truncated lysostaphin. Lysostaphin targets the cell wall peptidoglycan found in certain ''Staphylococci'' by cleaving its cross-linking pentaglycine bridges. Among others, it is effective for degrading ''Staphylocuccus aureus'' biofilms.<sup>1</sup> TU Eindhoven 2018 used lysostaphin to kill ''S. aureus'' for preventing wound infections.
+The biobrick contains the coding domain for truncated lysostaphin, based on the coding sequence derived from <partinfo>BBa_K748002</partinfo>. TU-Eindhoven 2018 used this part to produce lysostaphin from ''Escherichia coli'' to kill ''Staphylococcus aureus'' biofilms for the treatment of wound infections. For more information about our project, please visit our [http://2018.igem.org/Team:TU-Eindhoven wiki].
-The encoding part of the lysostaphin has been derived from <partinfo>BBa_K748002</partinfo>, made by iGEM Harbin 2012 and is also used by iGEM Stockholm 2016. iGEM Eindhoven 2018 codon optimized this lysostaphin construct.
+===Usage & Biology===
-===Usage and Biology===
 ====Lysostaphin====
-Lysostaphin is an antimicrobial agent produced by ''Staphylococcus simulans''. Lysostaphin belongs to the major class of antimicrobial proteins and peptides known as bacteriocins. Bacteriocins are proteins or peptides produced by bacteria, displaying a bactericidal activity against other subpopulations of bacteria. ''S. simulans'' has a protective immune system against lysostaphin, protecting itself from autolysis by its own produced proteins.<sup>2</sup>
+Lysostaphin is an antimicrobial agent produced by ''Staphylococcus simulans''. It targets the cell wall peptidoglycan found in certain Staphylococci by cleaving its cross-linking pentaglycine bridges. Among others, it is effective for degrading Staphylocuccus aureus biofilms.<sup>1</sup> The encoding part of the lysostaphin has been derived from <partinfo>BBa_K748002</partinfo>, which was made by iGEM Harbin 2012 and was also used by iGEM Stockholm 2016. iGEM Eindhoven 2018 codon optimized this lysostaphin construct. Lysostaphin belongs to the major class of antimicrobial proteins and peptides known as bacteriocins. Bacteriocins are proteins or peptides produced by bacteria, displaying a bactericidal activity against other subpopulations of bacteria.<sup>2</sup> The cell wall degradation capability of lysostaphin derives from its endopeptidase activity on pentaglycine cross-bridges in the peptidoglycan layer. Specific cleavage between the third and fourth glycine residue leads to the destruction of the peptidoglycan layer and subsequent lysis of the bacteria.
-Through cell-wall degradation of the target, lysostaphin has the ability to kill several ''Staphylococci'' strains. It owes its cell-wall degradation activity to the endopeptidase activity on pentaglycine cross-bridges in the peptidoglycan layer. Specific cleavage between the third and fourth glycine residue leads to the lysis of the peptidoglycan layer and death of the bacteria. Resistance to lysostaphin can occur however, due to a higher amount of serine residues instead of glycines in the peptidoglycan layer.<sup>3</sup>
 ====Sources====
 ) Tossavainen, H., Raulinaitis, V., Kauppinen, L., Pentikäinen, U., Maaheimo, H., & Permi, P. (2018). Structural and Functional Insights Into Lysostaphin–Substrate Interaction. ''Front Mol Biosci''.
+) Bastos, M. d., Coutinho, B. G., & Coelho, M. L. (2010). Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. ''Pharmaceuticals (Basel)'', 1139–1161.
-) Bastos, M. d., Coutinho, B. G., & Coelho, M. L. (2010). Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals (Basel) , 1139–1161.